Journal
LUPUS
Volume 13, Issue 5, Pages 377-380Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1191/0961203304lu1030oa
Keywords
CD 154; CD40 ligand; gp 39; review; systemic lupus erythematosus
Categories
Funding
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007304] Funding Source: NIH RePORTER
- NIAMS NIH HHS [AR07304] Funding Source: Medline
Ask authors/readers for more resources
CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expression of CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although marine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available